MP 106Alternative Names: MP-106
Latest Information Update: 26 Nov 2015
At a glance
- Originator Marathon Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 26 Nov 2015 Discontinued - Phase-III for Cancer in USA (unspecified route)